Patents Assigned to Neurogen Corporation, A Corporation of the State of Delaware
  • Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes
    Publication number: 20080032975
    Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R1 and R2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.
    Type: Application
    Filed: October 15, 2007
    Publication date: February 7, 2008
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: George Maynard, LingHong Xie, Stanislaw Rachwal
  • Bicyclic and tricyclic heteroaromatic compounds
    Publication number: 20060217384
    Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 28, 2006
    Applicant: Neurogen Corporation, A Corporation of the state of Delaware
    Inventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
  • Aryl fused substituted 4-oxy-pyridines
    Publication number: 20050154008
    Abstract: Disclosed are compounds of the formula: wherein X, Q, W and are as defined herein. These compounds are agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Application
    Filed: December 3, 2004
    Publication date: July 14, 2005
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Guolin Cai, Pamela Albaugh, Jun Yuan
  • Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
    Publication number: 20050038043
    Abstract: Compounds of Formula I are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
    Type: Application
    Filed: July 23, 2004
    Publication date: February 17, 2005
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Linghong Xie, Bingsong Han, Yuelian Xu, George Maynard, Bertrand Chenard, Kenneth Shaw, Yang Gao
  • 2-Aminoquinolinecarboxamides: neurokinin receptor ligands
    Publication number: 20040229907
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: June 14, 2004
    Publication date: November 18, 2004
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Jun Yuan, George D. Maynard, Alan Hutchison
  • 4-Imidazol-1-ylmethyl pyrimidine derivatives
    Publication number: 20040102457
    Abstract: The invention provides 4-imidazol-1-ylmethyl pyrimidine of the formula 1
    Type: Application
    Filed: November 6, 2003
    Publication date: May 27, 2004
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Linghong Xie, Bingsong Han, Yuelian Xu, George D. Maynard
  • 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
    Publication number: 20040083447
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: September 22, 2003
    Publication date: April 29, 2004
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Andrew Thurkauf, Xi Chen
  • Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
    Publication number: 20040023993
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: June 30, 2003
    Publication date: February 5, 2004
    Applicant: Neurogen Corporation A Corporation of the State of Delaware
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Substituted fused pyrazolecarboxylic acid arylamides and related compounds
    Publication number: 20030216379
    Abstract: Heterocyclic compounds such as 3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinoline-9-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinazoline-9-carboxylic acid arylamides, 2,4,5,6-Tetrahydro-1,2,6,7-tetraaza-as-indacene-8-carboxylic acid arylamides and related compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the treatment of anxiety, depression, sleep and seizure disorders, overdose with benzodiazepine drugs, Alzheimer's dementia, and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Intermediates useful for the synthesis of pyrazolecarboxylic acid arylamides are also provided.
    Type: Application
    Filed: February 7, 2003
    Publication date: November 20, 2003
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: George Maynard, Jun Yuan, Stanislaw Rachwal
  • Bicyclic and tricyclic hetroaromatic compounds
    Publication number: 20030181455
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: January 28, 2003
    Publication date: September 25, 2003
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
  • Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
    Publication number: 20030153754
    Abstract: Disclosed are the compounds of the formula: 1
    Type: Application
    Filed: November 22, 2002
    Publication date: August 14, 2003
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Pamela Albaugh, Gang Liu, Kenneth Shaw, Alan Hutchison
  • 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
    Publication number: 20030119851
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: June 28, 2002
    Publication date: June 26, 2003
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Andrew Thurkauf, Xi Chen
  • Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa Receptors
    Publication number: 20030092912
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: April 3, 2002
    Publication date: May 15, 2003
    Applicant: Neurogen Corporation, a corporation of the state of Delaware
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
    Publication number: 20030018025
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: May 28, 2002
    Publication date: January 23, 2003
    Applicant: Neurogen Corporation, Corporation of the State of Delaware
    Inventors: Andrew Thurkauf, Raymond F. Horvath, Jun Yuan, John M. Peterson
  • Certain fused pyrrolecarboxamides; a new class of GABA brain receptor
    Publication number: 20020198204
    Abstract: Disclosed are compounds of the formula 1
    Type: Application
    Filed: March 5, 2002
    Publication date: December 26, 2002
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Pamela Albaugh, Gang Liu, Alan Hutchison
  • Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
    Publication number: 20020156280
    Abstract: The present invention encompasses structures of the Formula 1
    Type: Application
    Filed: April 2, 2002
    Publication date: October 24, 2002
    Applicant: Neurogen Corporation, Corporation of the State of Delaware
    Inventors: Pamela A. Albaugh, Robert W. DeSimone, Gang Liu